HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. [electronic resource]
Producer: 20141126Description: 4867-76 p. digitalISSN:- 1476-5594
- Animals
- Antibiotics, Antineoplastic -- pharmacology
- Cell Line, Tumor
- Cell Survival -- drug effects
- Doxorubicin -- pharmacology
- Drug Synergism
- G2 Phase Cell Cycle Checkpoints
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Inhibitory Concentration 50
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Nude
- Small Cell Lung Carcinoma -- drug therapy
- Triazoles -- pharmacology
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Intramural
There are no comments on this title.
Log in to your account to post a comment.